TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06579040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monoplace Hyperbaric Chamber (Class III medical device)
Description: Participants in the intervention group will be triaged to the closest hyperbaric facility to their address and treated with 40 HBOTs (2 ATM for 90 mins, scheduled daily from Monday to Friday). As HBOT is not a service currently offered at Sunnybrook Hospital, all HBOT treatments will be provided at three collaborating outpatient facilities, Halton Hyperbaric Unit, Restore Hyperbaric Oxygen \& Medical Centre (CPSO-certified Level-II OHP), and Rouge Valley Hyperbaric Medical Centre. All three facilities have the exact same hyperbaric chambers, run by anesthesiologists with advanced training, thus treatments will be identical at all sites.
Study: NCT05758415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
Study: NCT05900323

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: enteral nutrition guidelines
Description: The nurses will be educated about the enteral nutrition guidelines. Then they will apply these guidelines on the participants during enteral nutrition procedure. After conducting the guidelines, the researcher will assess the effect of the guidelines on patients' outcomes.
Study: NCT04693221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choice of VNS set of parameters based on the lowest PLI
Description: Vagal nerve stimulation according to PLI results.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: EEG
Description: Patient will have an EEG and 12 sets of parameters will be tested. EEG results will be analyzed which will allow to determine the set involving the lowest phase lag index.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: Patient will have an EEG and 12 sets of parameters will be tested. EEG results will be analyzed which will allow to determine the set involving the lowest phase lag index.
Study: NCT06358027

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: The patients included in the study underwent lung imaging with lung ultrasound score twice, in the preoperative preparation room and in the postoperative recovery unit.Both lungs were determined as anterior and posterior axillary lines as anatomical markers and divided into a total of 12 regions, 4 in the anterior thoracic wall, 4 in the lateral wall, and 4 in the posterior region. In our study, we will use the modified LUS scoring, which has been shown to be more sensitive in the diagnosis of postoperative atelectasis in the recovery unit, based on existing literature reviews. The degree of the atelectasis will be determined according to do modified lung ultrasound score. Lung ultrasound score imaging of all patients was performed by the same anesthesiologist.

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: The patients included in the study underwent lung imaging with lung ultrasound score twice, in the preoperative preparation room and in the postoperative recovery unit.Both lungs were determined as anterior and posterior axillary lines as anatomical markers and divided into a total of 12 regions, 4 in the anterior thoracic wall, 4 in the lateral wall, and 4 in the posterior region. In our study, we will use the modified LUS scoring, which has been shown to be more sensitive in the diagnosis of postoperative atelectasis in the recovery unit, based on existing literature reviews. The degree of the atelectasis will be determined according to do modified lung ultrasound score. Lung ultrasound score imaging of all patients was performed by the same anesthesiologist.
Study: NCT05917964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-168 tablet
Description: LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-168 tablet
Description: LP-168 is a small molecule kinase inhibitor that is administered once daily via oral administration
Study: NCT04269785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon ablation
Description: Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using cryoballoon catheter (cold therapy)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Ablation aimed at performing pulmonary vein isolation for atrial fibrillation using radiofrequency catheter (heat therapy)
Study: NCT05758415

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive placebo s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
Study: NCT05169944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Anti-cancer therapeutic agent targeting the CD47-signal receptor protein-alpha (SIRP-alpha) axis
Study: NCT05174884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 22.2 mg Etonogestrel (ENG)
Description: Subdermal insertion of a single Casea S pellet (22.2 mg ENG) in healthy female participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 44.4 mg Etonogestrel (ENG)
Description: Subdermal insertion of a two Casea S pellet (44.4 mg ENG) in healthy female participants
Study: NCT05389423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 0.4 mg/m2/day administered by CIVI on days 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 0.4 mg/m2/day administered by CIVI on days 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/m2/day administered orally on days 1 to 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/m2/day administered orally on days 1 to 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 10 mg/m2/day administered by CIVI on days 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 10 mg/m2/day administered by CIVI on days 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg/m2/day administered by CIVI on days 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg/m2/day administered by CIVI on days 1 to 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 administered IV on day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 750 mg/m2 administered IV on day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered IV on day 1 (only for CD20+ tumors)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 administered IV on day 1 (only for CD20+ tumors)
Study: NCT05750173

Intervention type: OTHER
Intervention: Streamlining of the pre-procedural patient pathway
Description: Pre-TAVI ICA is associated with procedural risk, radiation, costs and requires hospitalization (2d).~Show that CTA is a viable alternative to rule out ≥50% left main coronary artery (LM) / prox. left anterior descending artery (LAD) stenosis.~An implementation of a standardized patient pathway which is reproducible, will help to streamline the pre-procedural workup of patients without compromising patient safety.

Intervention type: OTHER
Intervention: Streamlining of the pre-procedural patient pathway
Description: Pre-TAVI ICA is associated with procedural risk, radiation, costs and requires hospitalization (2d).~Show that CTA is a viable alternative to rule out ≥50% left main coronary artery (LM) / prox. left anterior descending artery (LAD) stenosis.~An implementation of a standardized patient pathway which is reproducible, will help to streamline the pre-procedural workup of patients without compromising patient safety.
Study: NCT05267106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: 13.5mg tablet taken every morning (unless otherwise directed) for 2 weeks and then 1 week off.
Study: NCT05475548

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: powerscope
Description: The PowerScope is the latest innovation in the treatment of Class II malocclusion which is a direct derivative of the Herbst Type II appliance. Dr. Andy Hayes worked in conjunction with American Orthodontics to develop PowerScope in 2016. This appliance supports intermaxillary wire-to-wire installation via a nut and hexagonal screw. A ball and socket joint is used to maximize lateral movement while improving patient comfort. The appliance is made up of a telescopic mechanism made up of an inner shaft/push rod, middle and outer tubing, and a spacer between the middle and outer tubing. A nickel-titanium (NiTi) spring provides a constant 260 g force. According to the present knowledge no studies regarding treatment outcomes of comprehensive fixed appliance treatment combined with the PowerScope in Class ΙII patients have been reported

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: powerscope
Description: The PowerScope is the latest innovation in the treatment of Class II malocclusion which is a direct derivative of the Herbst Type II appliance. Dr. Andy Hayes worked in conjunction with American Orthodontics to develop PowerScope in 2016. This appliance supports intermaxillary wire-to-wire installation via a nut and hexagonal screw. A ball and socket joint is used to maximize lateral movement while improving patient comfort. The appliance is made up of a telescopic mechanism made up of an inner shaft/push rod, middle and outer tubing, and a spacer between the middle and outer tubing. A nickel-titanium (NiTi) spring provides a constant 260 g force. According to the present knowledge no studies regarding treatment outcomes of comprehensive fixed appliance treatment combined with the PowerScope in Class ΙII patients have been reported
Study: NCT05892731

Intervention type: OTHER
Intervention: with depression
Description: age-related hearing loss with depression

Intervention type: OTHER
Intervention: without depression
Description: age-related hearing loss without depression
Study: NCT05178953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate 220 mg Capsules
Description: Zinc is an element that is involved in the activity of antioxidant enzymes. For example, the superoxide dismutase needs copper and zinc to function properly. Infertile men with asthenospermia receive 220 mg zinc sulfate tablets for 3 months
Study: NCT06403436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT125-802
Description: TT125-802 administered orally
Study: NCT06132945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib (40 mg PO daily)
Study: NCT06132945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (480 mg IV Day 1)
Study: NCT05178953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Oral use of pentoxifylline is effective in treating cardiovascular disease, cerebrovascular disease, and other conditions associated with local circulatory disorders. Pentoxifylline affects blood viscosity. Infertile men with asthenospermia receive 400 mg pentoxifylline tablets for 3 months
Study: NCT06260228

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HOme-Based Self-management and COgnitive Training CHanges lives (HOBSCOTCH)
Description: HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. HOBSCOTCH-PD is an adaptation of the HOBSCOTCH program for people with PD and incorporates education about Parkinson Disease and cognition into the education module.
Study: NCT04770337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STARSTIM device
Description: Cathodal Transcranial Direct Current Stimulation (tDCS). Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Intervention which uses enough currents to generate a sensory feedback similar to that of active stimulation via electrodes on the scalp
Study: NCT04362579

Intervention type: DEVICE
Intervention: wearable vital signs sensor
Description: vital signs monitoring during maternal non-stress testing or in the home setting

Intervention type: DEVICE
Intervention: wearable vital signs sensor
Description: vital signs monitoring during maternal non-stress testing or in the home setting
Study: NCT05139368

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy
Study: NCT02588846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'
Description: This intervention uses the simultaneous combined use of two technologies: 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'. kV Intrafraction Monitoring (KIM) measures the motion of tissues targeted for radiotherapy in real time using kV imaging.The multi-leaf collimator (MLC) reshapes the radiation beam to maximise dose to the target tissue and minimise dose to the surrounding healthy tissue. Combining KIM and MLC allows the shaped radiation beam to follow the moving target (the prostate) while remaining fixed on a stationary target (lymph nodes) that are also being treated at the same time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'
Description: This intervention uses the simultaneous combined use of two technologies: 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'. kV Intrafraction Monitoring (KIM) measures the motion of tissues targeted for radiotherapy in real time using kV imaging.The multi-leaf collimator (MLC) reshapes the radiation beam to maximise dose to the target tissue and minimise dose to the surrounding healthy tissue. Combining KIM and MLC allows the shaped radiation beam to follow the moving target (the prostate) while remaining fixed on a stationary target (lymph nodes) that are also being treated at the same time.
Study: NCT05895279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Watch MiCaP Research Digest video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Media Intervention
Description: Watch alternate video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study: NCT06294925

Intervention type: DRUG
Intervention: Etrasimod
Description: As provided in real world practice
Study: NCT06132945

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist.
Study: NCT05706116

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trichuris trichiura Egg Inoculum
Description: Trichuris trichiura Egg Inoculum that will be used in this study is manufactured by obtaining T. trichiura eggs from the feces of a chronically infected human volunteer, who is negative for HIV, HBV, and HCV. Fecal material is processed following a qualified standard procedure, and after isolating eggs, they are stored at 2-8oC until use. Controls for the manufacturing process are tests for viability (microscopy of larval hatching), species identification (PCR), and microbial bioburden of the eggs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trichuris trichiura Egg Inoculum
Description: Trichuris trichiura Egg Inoculum that will be used in this study is manufactured by obtaining T. trichiura eggs from the feces of a chronically infected human volunteer, who is negative for HIV, HBV, and HCV. Fecal material is processed following a qualified standard procedure, and after isolating eggs, they are stored at 2-8oC until use. Controls for the manufacturing process are tests for viability (microscopy of larval hatching), species identification (PCR), and microbial bioburden of the eggs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trichuris trichiura Egg Inoculum
Description: Trichuris trichiura Egg Inoculum that will be used in this study is manufactured by obtaining T. trichiura eggs from the feces of a chronically infected human volunteer, who is negative for HIV, HBV, and HCV. Fecal material is processed following a qualified standard procedure, and after isolating eggs, they are stored at 2-8oC until use. Controls for the manufacturing process are tests for viability (microscopy of larval hatching), species identification (PCR), and microbial bioburden of the eggs.
Study: NCT04997265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity anticoagulation
Description: Participants assigned to the low intensity anticoagulation strategy will receive anticoagulation at doses used for DVT prophylaxis in critically ill patients. The choice of agent (e.g. heparin or enoxaparin) and specific dosing will be at the discretion of the treating clinicians and will be prospectively recorded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Intensity Anticoagulation
Description: Patients assigned to the moderate intensity anticoagulation strategy will receive anticoagulation targeting a PTT goal of 40-60 seconds or anti-Xa level of 0.2 to 0.3 IU/mL. Choice of anticoagulant and monitoring strategy (PTT or anti-Xa level) will be at the discretion of the treating clinicians and will be prospectively recorded. Anticoagulant drips will be titrated according to institutional protocols. For patients who survive to decannulation, the infusion will be stopped one hour prior to decannulation.~This approach to anticoagulation reflects the current approach for patients receiving V-V ECMO at Vanderbilt University Medical Center and is similar to protocols widely adopted for patients receiving V-V ECMO at other centers.
Study: NCT05623345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Izokibep
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to izokibep
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to izokibep
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to izokibep
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)
Study: NCT05081583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hcl 1Mg/Ml Inj
Description: 0.5 mL of an intravenous solution (1 mg/mL) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hcl 1Mg/Ml Inj
Description: 0.5 mL of an intravenous solution (1 mg/mL) will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Hcl 1Mg/Ml Inj
Description: 0.5 mL of an intravenous solution (1 mg/mL) will be administered.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goldenseal (Hydrastis canadensis)
Description: Goldenseal (Solaray; Lot #1020199) is supplied as dried root powder in vegetable capsules, each containing 550 mg of herbal content. Goldenseal capsules will be administered with 240 mL of water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goldenseal (Hydrastis canadensis)
Description: Goldenseal (Solaray; Lot #1020199) is supplied as dried root powder in vegetable capsules, each containing 550 mg of herbal content. Goldenseal capsules will be administered with 240 mL of water.
Study: NCT05349682

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: dynamic contrast enhanced MRI
Description: An MRI study of the knee will be done to check the degree of osteoarthritis and blood flow to the affected knee. This scan will take about 1-2 hour(s).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: geniculate artery embolization
Description: The physician will perform a diagnostic angiography, where they will take pictures of vessels near the knee that will be treated. Once the artery to be treated is identified, the doctor will guide a thin wire called a microwire, and a plastic tube called a microcatheter to the targeted artery, and more pictures of vessels at the knee will be taken. This picture will be used to see if there are any abnormal vessels at the knee, such as abnormal blood flow, abnormal vessel connections (between the veins and arteries), or new blood vessel growth. Once the targeted artery at the knee is confirmed, the doctor will inject enough particle embolic (Embozene) to slow or stop the blood flow in the geniculate artery. Once all vessels are treated, a final angiogram (pictures of blood vessels) will be performed to ensure that the blood flow has slowed.
Study: NCT05868577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (CSI) with local anesthetic (LA)
Description: The PI will then administer the injection using an infracalcaneal needle peppering